Ricciuti B.; Baglivo S.; De Giglio A.; Chiari R., Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience, «THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE», 2018, 12, Article number: 1753466618808659, pp. 1 - 13 [articolo]Open Access
Baglivo S.; Ricciuti B.; Ludovini V.; Metro G.; Siggillino A.; De Giglio A.; Chiari R., Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation, «JOURNAL OF THORACIC ONCOLOGY», 2018, 13, pp. 145 - 147 [articolo]
De Giglio A.; Porreca R.; Brambilla M.; Metro G.; Prosperi E.; Bellezza G.; Pirro M.; Chiari R.; Ricciuti B., Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?, «THROMBOSIS RESEARCH», 2018, 163, pp. 51 - 53 [articolo]
Ricciuti B.; De Giglio A.; Mecca C.; Arcuri C.; Marini S.; Metro G.; Baglivo S.; Sidoni A.; Bellezza G.; Crino L.; Chiari R., Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib, «MEDICAL ONCOLOGY», 2018, 35, Article number: 72, pp. 1 - 18 [articolo]
Ricciuti B.; Baglivo S.; Paglialunga L.; De Giglio A.; Bellezza G.; Chiari R.; Crino L.; Metro G., Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2017, 9, pp. 387 - 403 [articolo]Open Access
Ricciuti B.; Leonardi G.C.; Ravaioli N.; De Giglio A.; Brambilla M.; Prosperi E.; Ribacchi F.; Meacci M.; Crino L.; Maiettini D.; Chiari R.; Metro G., Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient, «JOURNAL OF BREAST CANCER», 2016, 19, pp. 324 - 329 [articolo]
